GlassScriptPhysician profile
John M Manubay
NPI 1467538942
$10,847.89
in general payments reported to CMS, 2019-2025
47 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,187 · 2020: $2,018 · 2021: $1,750 · 2022: $1,589 · 2023: $2,173 · 2024: $949 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.36 |
| Education | $166.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,516.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,420.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $671.01 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $661.05 | 2019-2023 | Trelegy Ellipta, Bexsero, Shingrix |
| Pfizer INC. | $655.62 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $608.02 | 2019-2024 | |
| Abbvie INC. | $574.74 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $568.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.18 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Allergan, INC. | $410.45 | 2019-2020 | |
| Amgen INC. | $404.33 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $353.79 | 2019-2022 | |
| Astellas Pharma US INC | $334.05 | 2019-2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $207.24 | 2021-2024 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $197.99 | 2021-2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Manubay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.